N,2-dimethyl-N-(pyridin-3-ylmethyl)propan-1-amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,2-dimethyl-N-(pyridin-3-ylmethyl)propan-1-amine
• 化学式: C₁₁H₁₈N₂
• 分子量: 178.27
• InChiKey: CLQAVZUMBMNAMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20210147383A1

  公开（公告）日：2021-05-20

  Disclosed are compounds of Formula (I): or a salt thereof, wherein: Z is CR 6 R 6 or C═O; Ring A is: and R 1 , R 2 , R 3 , R 4 , R 5 , m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

  公开的化合物为Formula (I)的化合物或其盐，其中：Z为CR6R6或C═O；环A为：而R1、R2、R3、R4、R5、m和n在此处有定义。还公开了使用这些化合物抑制Helios蛋白的方法，以及包含这些化合物的药物组合物。这些化合物在治疗病毒感染和增生性疾病（如癌症）方面非常有用。
• CYCLIC PEPTIDES AND USE AS MEDICINES
  申请人：Fu Jiping

  公开号：US20140134132A1

  公开（公告）日：2014-05-15

  The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein the variables R 1 , R 2 , R 3 , R 4 , R 5 , and A-B are defined herein, which are non-immunosuppresive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.

  本发明提供了一种化合物I的公式；或其药学上可接受的盐，其中变量R1、R2、R3、R4、R5和A-B在此处定义，这些化合物是非免疫抑制剂、环肽酶结合剂、mPTP阻滞剂，因此可用于预防或治疗HCV感染、中风、多发性硬化、HBV感染、HPV感染、哮喘、癌症、肌萎缩症、败血症、缺血/再灌注损伤和心力衰竭等疾病或紊乱。
• BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US20160185818A1

  公开（公告）日：2016-06-30

  Both JNK and LRRK2 are associated with Parkinson's disease (PD), myocardial infarction (MI), and other medical disorders. Here we report a reasonably selective and potent kinase inhibitors (e.g., compounds 6 and 10) that bound to both JNK and LRRK2 (a dual inhibitor). A bidentate-binding strategy that simultaneously utilized the ATP hinge binding and a unique protein surface site outside of the ATP pocket was applied to the design and identification of this kind of inhibitor. Compound 6 was a potent JNK3 and modest LRRK2 dual inhibitor with an enzyme IC50 value of 12 nM and 99 nM (LRRK2-G2019S), respectively. 6 also exhibited good cell potency, inhibited LRRK2:G2019S induced mitochondrial dysfunction in SHSY5Y cells, and was demonstrated to be reasonably selective against a panel of 116 kinases from representative kinase families.

  JNK和LRRK2都与帕金森病（PD）、心肌梗死（MI）和其他医学疾病有关。在这里，我们报告了一种相对选择性和有效的激酶抑制剂（例如化合物6和10），它们结合了JNK和LRRK2（双重抑制剂）。采用一种双齿配体结合策略，同时利用ATP铰链结合和ATP口袋外的独特蛋白表面位点，设计和鉴定了这种抑制剂。化合物6是一种强效的JNK3和适度的LRRK2双重抑制剂，其酶IC50值分别为12 nM和99 nM（LRRK2-G2019S）。6还表现出良好的细胞效力，在SHSY5Y细胞中抑制了LRRK2：G2019S诱导的线粒体功能障碍，并被证明在代表性激酶家族的116个激酶面板中相对选择性较好。
• US9072696B2
  申请人：——

  公开号：US9072696B2

  公开（公告）日：2015-07-07
• US9850276B2
  申请人：——

  公开号：US9850276B2

  公开（公告）日：2017-12-26